Drug Trial Radar · NCT00145925
Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Apr 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11,140
Actual
Start
Jun 2001
Primary completion
Mar 2008
Study completion Mar 2008
Sponsor
- Lead sponsor
- The George InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut de Recherches Internationales Servier; University of Sydney; National Health and Medical Research Council, Australia
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 55 years, up to 110 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Perindopril-indapamideDrug
Gliclazide MR-based glucose loweringDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular causeTime frame: July 2001 - December 2007
- Composite of new or substantially worsening nephropathy or microvascular eye disease.Time frame: July 2001 - December 2007
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
The University of Melbourne
Melbourne, Victoria, Australia
University of Montreal
Montreal, Quebec, Canada
Cardiovascular Institute & Fu Wai Hospital
Beijing, Beijing Municipality, China
The Julius Center for Health Sciences and Primary Care
Utrecht, Utrecht, Netherlands
Imperial College School of Medicine
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.